A subsequent study comparing large cohorts of LRRK2-G2019S and GBA1 variant carriers vs. non-carriers (either with or without PD) did not find any difference in serum or CSF cytokine levels between groups [26]. This evidence concerns the gene GBA1 and Parkinson disease.